Phosphate ion

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Activated Charcoal Use in Chronic Kidney Disease Patients	2025/04/02	NCT06906874	Phase 2	Not yet recruiting	Mansoura University
Study on the Safety and Efficacy of Sodium Phosphate Powder for Intestinal Preparation in People Aged 50 to 70 Years Old	2024/10/22	NCT06652906	Phase 2	Recruiting	RenJi Hospital
A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors	2023/03/13	NCT05764915	Phase 1	Terminated	Regor Pharmaceuticals Inc.
Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure	2023/02/13	NCT05726097	Phase 3	Completed	Region Skane
Effect of Flow Rate and PH on Muscle Acidosis	2021/12/21	NCT05165277	Not Applicable	Terminated	Taipei Medical University Hospital
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder	2021/07/30	NCT04984512	Phase 2	UNKNOWN	Sunshine Lake Pharma Co., Ltd.
Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease	2021/01/29	NCT04730245	Phase 1	Completed	Torre Médica Santé
Effect of Chewing a Calcium Supplement Before Fluoride Rinse on Salivary Fluoride	2020/11/06	NCT04620252	Early Phase 1	Completed	University of Michigan
Randomized Trial Comparing Carbonated Drink With Water as a Solvent for Colonoscopy Solution	2020/03/20	NCT04316858	Not Applicable	Completed	Dow University of Health Sciences
Chronic Non Bacterial Prostatitis: a Trial of TRUS Guided Injection of Betamethason	2019/12/26	NCT04210739	Early Phase 1	UNKNOWN	Cairo University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Digoxin	Cardinal Health 107, LLC	55154-5106	INTRAVENOUS, INTRAMUSCULAR	N/A	12/12/2022
Prenaissance	Acella Pharmaceuticals, LLC	42192-341	ORAL	160 mg in 1 1	9/11/2018
Elliotts B	QOL Medical, LLC	67871-007	INTRATHECAL	2 mg in 10 mL	3/20/2012
Elliotts B	Lukare Medical, LLC	55792-007	INTRATHECAL	2 mg in 10 mL	11/16/2018

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

FDA Manufacturing Issues Delay Unicycive's Kidney Disease Drug Approval Process

a month ago

The FDA has identified manufacturing deficiencies at a third-party vendor for Unicycive Therapeutics' oxylanthanum carbonate, an investigational oral phosphate binder for kidney disease patients on dialysis.

FDA Accepts Unicycive's Oxylanthanum Carbonate (OLC) Application for Hyperphosphatemia Treatment

8 months ago

The FDA has accepted Unicycive Therapeutics' NDA for Oxylanthanum Carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access